Research

Traditional Indian medicine and homeopathy for HIV/AIDS: a review of the literature

M Fritts¹ , CC Crawford¹ , D Quibell¹ , A Gupta² , WB Jonas¹ , I Coulter³ and SA Andrade⁴

¹  Samueli Institute, 1737 King Street, Ste. 600 Alexandria, VA 22314, USA

²  Johns Hopkins University School of Medicine, Center for Clinical Global Health Education, 600 North Wolfe Street, Jefferson 2-127 Baltimore, MD 21287, USA

³  UCLA School of Dentistry, 63-037A CHS, 10833 Le Conte Ave, Los Angeles, CA 90095, USA

⁴  Johns Hopkins University School of Medicine, Division of Infectious Diseases, 1830 East Monument Street, Ste. 8074 Baltimore, MD 21287, USA

author email corresponding author email

AIDS Research and Therapy 2008, 5:25doi:10.1186/1742-6405-5-25

Published:	22 December 2008

Abstract

Background

Allopathic practitioners in India are outnumbered by practitioners of traditional Indian medicine and homeopathy (TIMH), which is used by up to two-thirds of its population to help meet primary health care needs, particularly in rural areas. India has an estimated 2.5 million HIV infected persons. However, little is known about TIMH use, safety or efficacy in HIV/AIDS management in India, which has one of the largest indigenous medical systems in the world. The purpose of this review was to assess the quality of peer-reviewed, published literature on TIMH for HIV/AIDS care and treatment.

Results

Of 206 original articles reviewed, 21 laboratory studies, 17 clinical studies, and 6 previous reviews of the literature were identified that covered at least one system of TIMH, which includes Ayurveda, Unani medicine, Siddha medicine, homeopathy, yoga and naturopathy. Most studies examined either Ayurvedic or homeopathic treatments. Only 4 of these studies were randomized controlled trials, and only 10 were published in MEDLINE-indexed journals. Overall, the studies reported positive effects and even "cure" and reversal of HIV infection, but frequent methodological flaws call into question their internal and external validity. Common reasons for poor quality included small sample sizes, high drop-out rates, design flaws such as selection of inappropriate or weak outcome measures, flaws in statistical analysis, and reporting flaws such as lack of details on products and their standardization, poor or no description of randomization, and incomplete reporting of study results.

Conclusion

This review exposes a broad gap between the widespread use of TIMH therapies for HIV/AIDS, and the dearth of high-quality data supporting their effectiveness and safety. In light of the suboptimal effectiveness of vaccines, barrier methods and behavior change strategies for prevention of HIV infection and the cost and side effects of antiretroviral therapy (ART) for its treatment, it is both important and urgent to develop and implement a rigorous research agenda to investigate the potential risks and benefits of TIMH and to identify its role in the management of HIV/AIDS and associated illnesses in India.